Literature DB >> 29031609

Multi-atlas-based segmentation of prostatic urethra from planning CT imaging to quantify dose distribution in prostate cancer radiotherapy.

Oscar Acosta1, Eugenia Mylona2, Mathieu Le Dain2, Camille Voisin2, Thibaut Lizee2, Bastien Rigaud2, Carolina Lafond3, Khemara Gnep3, Renaud de Crevoisier3.   

Abstract

BACKGROUND AND
PURPOSE: Segmentation of intra-prostatic urethra for dose assessment from planning CT may help explaining urinary toxicity in prostate cancer radiotherapy. This work sought to: i) propose an automatic method for urethra segmentation in CT, ii) compare it with previously proposed surrogate models and iii) quantify the dose received by the urethra in patients treated with IMRT.
MATERIALS AND METHODS: A weighted multi-atlas-based urethra segmentation method was devised from a training data set of 55 CT scans of patients receiving brachytherapy with visible urinary catheters. Leave-one-out cross validation was performed to quantify the error between the urethra segmentation and the catheter ground truth with two scores: the centerlines distance (CLD) and the percentage of centerline within a certain distance from the catheter (PWR). The segmentation method was then applied to a second test data set of 95 prostate cancer patients having received 78Gy IMRT to quantify dose to the urethra.
RESULTS: Mean CLD was 3.25±1.2mm for the whole urethra and 3.7±1.7mm, 2.52±1.5mm, and 3.01±1.7mm for the top, middle, and bottom thirds, respectively. In average, 53% of the segmented centerlines were within a radius<3.5mm from the centerline ground truth and 83% in a radius<5mm. The proposed method outperformed existing surrogate models. In IMRT, urethra DVH was significantly higher than prostate DVH from V74Gy to V79Gy.
CONCLUSION: A multi-atlas-based segmentation method was proposed enabling assessment of the dose within the prostatic urethra.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atlas-based segmentation; Dose computation; Prostate cancer radiotherapy; Urethra segmentation; Urinary toxicity

Mesh:

Year:  2017        PMID: 29031609     DOI: 10.1016/j.radonc.2017.09.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Automated Segmentation of Tissues Using CT and MRI: A Systematic Review.

Authors:  Leon Lenchik; Laura Heacock; Ashley A Weaver; Robert D Boutin; Tessa S Cook; Jason Itri; Christopher G Filippi; Rao P Gullapalli; James Lee; Marianna Zagurovskaya; Tara Retson; Kendra Godwin; Joey Nicholson; Ponnada A Narayana
Journal:  Acad Radiol       Date:  2019-08-10       Impact factor: 3.173

2.  CT male pelvic organ segmentation using fully convolutional networks with boundary sensitive representation.

Authors:  Shuai Wang; Kelei He; Dong Nie; Sihang Zhou; Yaozong Gao; Dinggang Shen
Journal:  Med Image Anal       Date:  2019-03-21       Impact factor: 8.545

3.  CT prostate segmentation based on synthetic MRI-aided deep attention fully convolution network.

Authors:  Yang Lei; Xue Dong; Zhen Tian; Yingzi Liu; Sibo Tian; Tonghe Wang; Xiaojun Jiang; Pretesh Patel; Ashesh B Jani; Hui Mao; Walter J Curran; Tian Liu; Xiaofeng Yang
Journal:  Med Phys       Date:  2019-12-03       Impact factor: 4.071

4.  Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra.

Authors:  Mason J Belue; Stephanie A Harmon; Krishnan Patel; Asha Daryanani; Enis Cagatay Yilmaz; Peter A Pinto; Bradford J Wood; Deborah E Citrin; Peter L Choyke; Baris Turkbey
Journal:  Acad Radiol       Date:  2022-02-16       Impact factor: 5.482

5.  The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy.

Authors:  Yasuhiro Dekura; Kentaro Nishioka; Takayuki Hashimoto; Naoki Miyamoto; Ryusuke Suzuki; Takaaki Yoshimura; Ryuji Matsumoto; Takahiro Osawa; Takashige Abe; Yoichi M Ito; Nobuo Shinohara; Hiroki Shirato; Shinichi Shimizu
Journal:  Radiat Oncol       Date:  2019-12-12       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.